DXP (DXPE) Q3 2026 Earnings Call Transcript

DXP Enterprises reported record Q3 2026 sales of $587.2 million, up 14.3% year over year, including 8.7% organic growth. Adjusted EBITDA rose 19% to $67.3 million and diluted EPS increased to $1.64 from $1.31, while gross margin declined to 30.7% from 31.4% on sales mix and quarterly free cash flow fell to $14.4 million from $28.1 million as working capital increased. Nine-month free cash flow more than tripled to $70.5 million; the company had $218.8 million in cash, no ABL borrowings, and agreed to acquire MDS of Michigan on Nov. 1, 2026.∎

Analysis

DXPE’s earnings quality is more mixed than the headline operating leverage suggests. Service Centers appear to be the cleaner organic engine; IPS growth is much more acquisition-dependent, while DXP Water’s rapid expansion may require sustained working-capital funding before it contributes proportionately to cash. The key near-term test is not another sales record but whether receivables and project costs convert to cash as management expects. If not, acquisition capacity and the equity multiple could be constrained despite reported EBITDA growth.

The September-to-October daily-sales pullback is an early watch item, not yet evidence of a demand break: quarter-end shipment timing can distort the comparison. But it raises the bar for Q4, especially as a large engineered project ships out. Backlog growth excluding that project supports activity into 2027, though backlog is not equivalent to profitable, timely cash conversion. Gross-margin mix also matters: expense leverage can mask weaker economics temporarily, but cannot indefinitely offset lower contribution per sales dollar.

Near term, the print supports a constructive bias, offset by cash-conversion risk. Over 1–3 months, monitor Q4 working capital, October/November sales cadence, and post-project IPS margins. Over 6–18 months, water-platform integration and acquisition returns—not deal count—determine whether DXPE merits a higher-quality growth profile. The contrarian risk is that investors capitalize acquisition-assisted growth as organic compounding before the cash and margin evidence is established. SPGI’s rating action is a credit signal, not an operating catalyst for SPGI.

Key Decisions for Investors

• Avoid chasing the earnings print; keep DXPE on a conditional long watchlist and consider initiating only if the next update confirms working-capital normalization alongside continued organic growth.
• Use the next quarter as the catalyst check: track receivable days, costs in excess of billings, free-cash-flow conversion, and organic IPS growth separately from acquired sales. Failure to improve cash conversion would invalidate the constructive thesis even if EBITDA rises.
• Do not assume the engineered-project shipment creates a durable margin rebound. Require segment margin recovery after the project rolls off; continued gross-margin erosion despite sales growth is a reason to reduce or avoid exposure.
• Treat the October sales deceleration as an alert rather than a short signal. A sustained weakening in daily sales or backlog, especially alongside lower Service Centers activity, would support a more defensive stance; one monthly data point is insufficient.